Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management
Anna S Lok, Fabien Zoulim, Stephen Locarnini, Angeline Bartholomeusz, Marc G Ghany, Jean-Michel Pawlotsky, Yun-Fan Liaw, Masashi Mizokami, Carla Kuiken, Hepatitis B Virus Drug Resistance Working Group, Anna S Lok, Fabien Zoulim, Stephen Locarnini, Angeline Bartholomeusz, Marc G Ghany, Jean-Michel Pawlotsky, Yun-Fan Liaw, Masashi Mizokami, Carla Kuiken, Hepatitis B Virus Drug Resistance Working Group
Abstract
Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy.
Source: PubMed